PAVmed Inc (NASDAQ:PAVM) does about 66.57K shares in volume on a normal day but saw 1664534 shares change hands in the recent trading day. The company now has a market cap of 6.86M USD. Its current market price is $0.64, marking an increase of 10.82% compared to the previous close of $0.58. The 52 week high reached by this stock is $3.83 whilst the lowest price level in 52 weeks is $0.58.
PAVmed Inc (PAVM) has a 20-day trading average at $0.8468 and the current price is -83.15% off the 52-week high compared with 10.82% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.9732 and its 200-day simple moving average is $1.3028. If we look at the stock’s price movements over the week, volatility stands at 17.78%, which decreases to 13.25% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 32.74 to suggest the stock is neutral.
The consensus objective for the share price is $9.00, suggesting that the stock has a potential upside of 92.89% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 30, 2021 when Cantor Fitzgerald initiated the stock to “Overweight” and issued a price target of $8. Maxim Group initiated its price target at $5.
The current price level is -23.84%, -33.72%, and -50.49% away from its SMA20, SMA50, and SMA200 respectively, with the PAVM price moving above the 50-day SMA on current market day. PAVmed Inc (PAVM) stock is down -10.47% over the week and -36.14% over the past month. Its price is -81.84% year-to-date and -80.46% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.4 and -2.69 for whole year. Expected sales for next quarter are $21k, which analysts say will come at $3.01M for the current fiscal year and next year at $12.82M. In addition, estimates put the company’s current quarterly revenue at an average of $20k.
To reach the target analysts have set, the stock logically needs to grow 92.89 percent from here.
Outstanding shares total 10.66M with insiders holding 10.39% of the shares and institutional holders owning 14.60% of the company’s common stock. The beta has a value of 0.69. Price to sales ratio is 1.70.
